Biology of Blood and Marrow Transplantation
Volume 15, Issue 6 , Pages 653-655 , June 2009

Transplantation Conditioning Regimens: Can We Say It Better?

  • H. Joachim Deeg

      Affiliations

    • Corresponding Author InformationCorrespondence and reprint requests: H. Joachim Deeg, MD, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1-100, PO Box 19024, Seattle, WA 98109-1024.

Received 2 March 2009 ,Accepted 10 March 2009.

References 

  1. Thomas ED, Lochte HL, Lu WC, et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257:491–496
  2. Burchenal JH, Oettgen HF, Holmberg EAD, et al. Effect of total body irradiation on the transplantability of mouse leukemias. Cancer Res. 1960;20:425
  3. Barnes DWH, Corp MJ, Loutit JF, et al. Treatment of murine leukaemia with x-rays and homologous bone marrow: preliminary communication. BMJ. 1956;2:626–627
  4. Barnes DWH, Loutit JF. Treatment of murine leukaemia with x-rays and homologous bone marrow II. Br J Haematol. 1957;3:241–252
  5. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med. 1979;300:1068–1073
  6. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562
  7. Gale RP, Horowitz MM, Ash RC, et al. Identical twin bone marrow transplants for leukemia. Ann Intern Med. 1994;120:646–652
  8. Fefer A, Cheever MA, Thomas ED, et al. Bone marrow transplantation for refractory acute leukemia in 34 patients with identical twins. Blood. 1981;57:421–430
  9. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol. 1996;14:220–226
  10. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 1995;86:2041–2050
  11. Slavin S, Or R, Nagler A, et al. Allogeneic cell therapy (alloCT) for prevention of relapse in high-risk acute leukemia following allogeneic bone marrow transplantation: control of GVHD by graded increments of donor lymphocyte infusion [abstract]. Blood. 1996;88:418a
  12. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89:3048–3054
  13. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344:175–181
  14. Schmitz N, Eapen M, Horowitz MM, et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood. 2006;108:4288–4290
  15. Mohty M, Blaise D, Faucher C, et al. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 2005;106:4407–4411
  16. Mohty M, Nagler A, Killmann NM. Reduced-intensity conditioning allogeneic stem cell transplantation: hype, reality or time for a rethink?. Leukemia. 2006;20:1653–1654
  17. Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005;35:943–951
  18. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:865–872
  19. Ho AYL, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan and alemtuzumab (FBC) conditioning. Blood. 2004;104:1616–1623
  20. Deeg HJ, Maris MB, Scott BL, et al. Optimization of allogeneic transplant conditioning: not the time for dogma. Leukemia. 2006;20:1701–1705
  21. Ahmed N, Leung KS, Rosenblatt H, et al. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008;14:1298–1304
  22. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102:756–762
  23. Couriel DR, Saliba RM, Giralt S, et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2004;10:178–185

 Financial disclosure: See Acknowledgments on page 654.

PII: S1083-8791(09)00151-7

doi: 10.1016/j.bbmt.2009.03.007

Biology of Blood and Marrow Transplantation
Volume 15, Issue 6 , Pages 653-655 , June 2009

Article Tools